# US 2021/0330711 A1 · Compositions with antiviral activity and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330711 A1
- Document ID: US20210330711A1
- Status: Published application
- Kind: A1
- Application number: 17/237,239
- Filed: 2021-04-22
- Published: 2021-10-28
- Earliest claimed: 2020-04-22
- Assignees: Fettech, LLC
- Applicants: Fettech, LLC
- Inventors: Clay FETTE
- Web page: https://patentgrep.com/patent/US20210330711A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/26: Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- A61K 9/10: Dispersions; Emulsions
- A61K 35/42: Respiratory system, e.g. lungs, bronchi or lung cells
- A61P 31/12: Antivirals
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Compositions that include extracellular matrix (ECM) materials having antiviral activity and methods of use thereof are disclosed. The compositions may be administered to a subject in need thereof, e.g., subject having a viral infection or being suspected of having a viral infection. The virus may be an enveloped virus, such as a coronavirus.

## Claims

### Claim 1

A method of treating a subject, the method comprising:
administrating a composition to the subject, wherein the composition comprises at least one extracellular matrix (ECM) material, the at least one ECM material being derived from tissue chosen from spleen, lung, gall bladder, bone marrow, pancreas, liver, or a mixture thereof, the at least one ECM material retaining native bioactive components of the tissue;
wherein the subject is infected or suspected of being infected with a virus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition reduces a viral load of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has an infectious viral disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the virus is an enveloped virus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the virus is a coronavirus or an adenovirus.

### Claim 6 (depends on 5)

The method of claim 5, wherein the virus is severe acute respiratory syndrome-associated coronavirus (SARS-CoV), severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), or Middle East respiratory syndrome coronavirus (MERS-CoV).

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition inactivates at least a portion of a virus population of the subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a human or a non-human mammal.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition comprises at least two different types of ECM materials.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition comprises spleen ECM material and lung ECM material.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is in particulate form, gel form, or liquid form.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is administered via inhalation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered intravenously.

### Claim 14

A method of treating a subject, the method comprising:
administrating a composition to the subject, wherein the composition comprises at least two different extracellular matrix (ECM) materials, the ECM materials being derived from a tissue independently chosen from spleen tissue, lung tissue, gall bladder tissue, bone marrow tissue, pancreas tissue, or liver tissue;
wherein the subject is infected or suspected of being infected with a virus; and
wherein the virus is an enveloped virus.

### Claim 15 (depends on 14)

The method of claim 14, wherein the virus is a coronavirus or an adenovirus.

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject has an infectious viral disease.

### Claim 17 (depends on 14)

The method of claim 14, wherein the composition is administered via inhalation.

### Claim 18 (depends on 14)

The method of claim 14, wherein the composition is administered intravenously.

### Claim 19

A method of treating a subject, the method comprising:
administrating a composition to the subject, wherein the composition comprises at least one extracellular matrix (ECM) material, the at least one ECM material being derived from a tissue chosen from spleen tissue, lung tissue, gall bladder tissue, bone marrow tissue, pancreas tissue, or liver tissue;
wherein the subject is infected or suspected of being infected with a virus; and
wherein the subject is a human or a non-human mammal.

### Claim 20 (depends on 19)

The method of claim 19, wherein the virus is a coronavirus or an adenovirus.
